MLTX: Reports Phase 3 VELA Results
MoonLake announces Phase 3 VELA program week 52 results showing 67.2% of sonelokimab-treated patients achieving HiSCR75 in moderate-to-severe hidradenitis suppurativa
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.